March 13 (Reuters) - Ionis Pharmaceuticals said on Wednesday that its experimental drug to treat a type of fatty liver disease met the primary goal of a mid-stage trial. (Reporting by Pratik Jain in Bengaluru; Editing by Savio D'Souza)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.47 USD | -1.72% | -8.40% | -21.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.98% | 5.76B | |
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial